Skip to main content

Biden administration asserts power to seize drug patents in move to slash high prices

The Biden administration unveiled a new framework outlining the factors federal agencies should consider in determining whether to use march-in rights.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.